Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
SRZN · against 397 other Healthcare companies of similar size
Ranked #288 of 398 · scores higher than 28% of peers · safety percentile 31
Bars: peers in each 10-point band of the safety percentile (higher = safer; 67+ earns the lower-risk grade)35 peers with a safety percentile of 30–39, including SRZN · Click a bar to see the companies
Mainly because of its debt / equity, which is weaker than most Healthcare peers.
Risk is relative to the sector, not a bankruptcy probability. Banks and brokers carry high leverage by design, and share buybacks can shrink equity and current assets, which raises debt/equity on paper.
| Metric | SRZN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Debt / equityLower is better · 364 reported | Not reported | 0.19× | — | — | 33% |
| BetaLower is better · 382 reported | 0.56 | 0.45 | 43% | 33% | |
| Current ratioHigher is better · 390 reported | 12.14× | 3.01× | 86% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Safety | Overall |
|---|---|---|---|---|
| 1 | 186M USD | 100 | 52 | |
| 2 | 421M USD | 99 | 52 | |
| 3 | 261M USD | 99 | 97 | |
| 4 | 397M USD | 99 | 37 | |
| 5 | 455M USD | 99 | 53 | |
| 284 | 4.4B CNY (≈$612M) | 32 | 33 | |
| 285 | 3.1B HKD (≈$396M) | 32 | 61 | |
| 286 | 470M EUR (≈$517M) | 31 | 56 | |
| 287 | 35.2B JPY (≈$240M) | 31 | 12 | |
| 288 | 354M USD | 31 | 13 | |
| 289 | 44.2B JPY (≈$301M) | 31 | 64 | |
| 290 | 3.5B CNY (≈$496M) | 31 | 18 | |
| 291 | 188M CHF (≈$216M) | 30 | 74 | |
| 292 | 433M USD | 30 | 81 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score